Q-omics provides the consensus-scored CYCSP25 profile across patient tissues and cancer cell-line models. CYCSP25 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CYCSP25 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, CYCSP25 RNA expression shows 7,372 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, KIRC, and HNSC as cancer lineages where CYCSP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP25 survival associations across molecular data types. CYCSP25 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP25 RNA expression–survival associations across cancer types. High CYCSP25 expression shows unfavorable associations in UVM, LGG, ACC and THCA, but favorable associations in ESCA and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for CYCSP25 RNA expression.
This table summarizes CYCSP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP25 shows lower tumor expression in KIRC and higher tumor expression in BRCA. The KIRC box plot shows higher CYCSP25 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .002).
This table shows molecular features associated with CYCSP25 in patient tissues and cancer cell lines. In patient samples, CYCSP25 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
